Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 29.17 USD 1.92% Market Closed
Market Cap: 4.8B USD
Section:
 

Relative Value

The Relative Value of one ALKS stock under the Base Case scenario is 35.23 USD. Compared to the current market price of 29.17 USD, Alkermes Plc is Undervalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALKS Relative Value
Base Case
35.23 USD
Undervaluation 17%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.2
P/S
P/S
Price to Sales
3.2
vs History
60
vs Industry
68
Median 3Y
3.2
Median 5Y
3.3
Industry
7.9
Forward
3.2
More Details
14.2
P/E
P/E
Price to Earnings
14.2
vs History
23
vs Industry
9
Median 3Y
14
Median 5Y
-27.1
Industry
24
Forward
19.4
More Details
8.9
P/OCF
P/OCF
Price to OCF
8.9
vs History
90
vs Industry
12
Median 3Y
11.5
Median 5Y
24.2
Industry
21.6
More Details
9.8
P/FCFE
P/FCFE
Price to FCFE
9.8
vs History
82
vs Industry
3
Median 3Y
12.5
Median 5Y
16.3
Industry
23.7
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
92
vs Industry
25
Median 3Y
3.6
Median 5Y
3.6
Industry
3.4
More Details
2.4
EV/S
EV/S
Enterprise Value to Sales
2.4
vs History
77
vs Industry
61
Median 3Y
2.6
Median 5Y
2.8
Industry
8.3
Forward
2.5
More Details
2.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.8
vs History
79
vs Industry
62
Median 3Y
3.1
Median 5Y
3.4
Industry
10.3
More Details
9.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.5
vs History
46
vs Industry
11
Median 3Y
8.7
Median 5Y
9.3
Industry
6.7
Forward
9.6
More Details
10.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.3
vs History
22
vs Industry
10
Median 3Y
10
Median 5Y
-24
Industry
7.2
Forward
14.2
More Details
6.9
EV/OCF
EV/OCF
Enterprise Value to OCF
6.9
vs History
90
vs Industry
13
Median 3Y
9.4
Median 5Y
21.5
Industry
8.2
More Details
7.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
7.5
vs History
82
vs Industry
9
Median 3Y
10.4
Median 5Y
12.8
Industry
6.7
More Details
3.2
EV/IC
EV/IC
Enterprise Value to IC
3.2
vs History
42
vs Industry
34
Median 3Y
3.3
Median 5Y
3.2
Industry
5.7
More Details

Multiples Across Competitors

ALKS Competitors Multiples
Alkermes Plc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Alkermes Plc
NASDAQ:ALKS
4.8B USD 3.2 14.2 9.5 10.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 794 036.5 -160 618 -195 041.5 -192 815.9
US
Abbvie Inc
NYSE:ABBV
395.9B USD 6.6 168.6 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
170.8B USD 4.7 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
153B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD 9.7 30.8 22.6 23.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.7 -531.9 -579.2 -563.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.2 16.3 18.5
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.8 13.3 16.5
NL
argenx SE
XBRU:ARGX
46.3B EUR 15.1 35.5 61.4 63.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.4B USD 16.9 1 248.3 164.2 199.1
P/S Multiple
Revenue Growth P/S to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average P/S: 3 072 381.1
3.2
6%
0.5
FR
Pharnext SCA
OTC:PNEXF
33 794 036.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
10%
1
US
E
Epizyme Inc
F:EPE
2 084.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.1
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.9
46%
0.4
P/E Multiple
Earnings Growth PEG
IE
Alkermes Plc
NASDAQ:ALKS
Average P/E: 175.3
14.2
-12%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 618 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.8
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
35.5
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 248.3
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBITDA: 37.1
9.5
2%
4.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 041.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
NL
argenx SE
XBRU:ARGX
61.4
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
164.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBIT: 42.7
10.3
-7%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 815.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
63.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
199.1
N/A N/A

See Also

Summary
ALKS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALKS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALKS stock valuation using valuation multiples.
Wall Street Estimates
ALKS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALKS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.